ImmunomeIMNM +2.17%44 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates IMNM with a GF Score™ of 44/100 and a GF Value™ of $2.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Immunome ranks worse than 90.83% on this metric.
The historical rank and industry rank for Immunome's OCF Margin % or its related term are showing as below:
IMNM'
s OCF Margin % Range Over the Past 10 Years
Min: -2750.6 Med: -1225.46 Max: -53.99
Current: -4894.2
During the past 8 years, the highest OCF Margin % of Immunome was -53.99%. The lowest was -2750.60%. And the median was -1225.46%.
IMNM's OCF Margin % is ranked worse than 90.83% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs IMNM: -4894.20
Immunome OCF Margin % Related Terms
Immunome OCF Margin % Historical Data
* Premium members only.
The historical data trend for Immunome's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunome's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunome OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunome's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Immunome's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunome (IMNM) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immunome and its competitors. According to the industry distribution chart, Immunome ranks #872 out of 960 companies in the Biotechnology industry, placing it in the top 90.8%.
Is Immunome's OCF Margin % too high?
Immunome's current OCF Margin % is 0.00%. Based on the distribution chart, Immunome ranks #872 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunome has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's OCF Margin % compare to CLDX and ELVN?
According to the Biotechnology industry distribution chart, Immunome ranks #872 out of 960 companies for OCF Margin %. This places Immunome in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immunome and its competitors. Immunome's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.02, compared to a current price of $19.77 — trading 878.7% above its estimated fair value. The current OCF Margin % is 0.00%. Immunome's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Immunome (IMNM), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunome (IMNM) Overvalued in 2026?
Based on GuruFocus' analysis, Immunome stock appears to be overvalued.
The current stock price of $19.77 is trading 878.7% above its estimated GF Value™ of $2.02.
GuruFocus considers Immunome to be Significantly Overvalued.
Key valuation signals for IMNM:
OCF Margin %: 0.00%
GF Value™: $2.02 vs. price of $19.77 (878.7% above fair value)
No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score
Get the complete analysis for IMNM
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMNM has been successfully added to your 
